Branded Products

green round medication tablets

With an accelerated commitment to expansion and R&D, Chartwell is paving the way to a strong branded portfolio. By isolating unmet needs and applying our API development, manufacturing, and logistics expertise gained from years of excellence in contract manufacturing, we're uniquely positioned to bring value to the market under our own label.

Our portfolio currently contains one 505(b)(2) NDA and three standard NDAs, with more to come. The addition of Chartwell Labs and Chartwell Actives, coupled with an ongoing acquisition plan of strategic industry interests, ensures that the market will be seeing many more exciting branded products from Chartwell in the coming years.

Our Growing Brand

Chartwell's first branded drug, LymePak, was approved by the FDA in June of 2018.

Learn more about LymePak.
chartwell lymepak for treatment of lyme disease
Chartwell Pharmaceuticals